Abstract
We report our experience with a patient with metastatic differentiated radioactive iodine-refractory thyroid cancer treated with vandetanib. We describe the potential side effects of this drug and the treatment of toxicities. The goal is to allow patients to remain on their full dose of vandetanib for as long as their treatment is indicated. A combination of early recognition and intervention for adverse events, patient education, and an open dialogue between patients and their multidisciplinary healthcare team, with timely reporting of adverse events, will allow for effective management of side effects and minimize the need for dose reduction or discontinuation of tyrosine kinase inhibitor therapy.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002;62:7284–90.
Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002;62:4645–55.
https://clinicaltrials.gov/ct2/show/NCT01876784?term=vandetanib&rank=6
Grande E, Kreissl MC, Filetti S, et al. Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv Ther. 2013;30:945–66.
Cooper MR, Yi SY, Alghamdi W, Shaheen DJ, Steinberg M. Vandetanib for the treatment of medullary thyroid carcinoma. Ann Pharmacother. 2014;48:387–94.
Lenihan DJ, Kowey PR. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist. 2013;18:900–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Granata, R., Locati, L., Licitra, L. (2016). A Patient with Advanced Differentiated Radioactive Iodine-Refractory Thyroid Cancer Receiving Tyrosine Kinase Inhibitor Treatment: Managing Hypertension, QTc Prolongation, Dermatologic and Gastrointestinal Adverse Events. In: Cooper, D., Durante, C. (eds) Thyroid Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-22401-5_37
Download citation
DOI: https://doi.org/10.1007/978-3-319-22401-5_37
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-22400-8
Online ISBN: 978-3-319-22401-5
eBook Packages: MedicineMedicine (R0)